Integer shareholders approve getting acquired by KKR
Integer (ITGR) shareholders approved a $5.7B acquisition by KKR. The vote was 26,065,335 for, 10,513 against, with 1,993 abstaining. The deal, announced in August, is expected to close by the end of 2026, pending regulatory approvals. Integer is a medical device CDMO serving cardiovascular and neuromodulation markets. The company expects increased flexibility and long-term capital as a KKR portfolio company.
How this was made
The 30-second read
Why it matters
The approval removes a key execution risk, likely prompting a short‑term rally in ITGR as the market prices in the transaction premium and future capital infusion.
Market read
Primary M&A disclosure for a mid‑cap US‑listed medtech company; immediate trading relevance for ITGR.
What to watch
Regulatory approvals and financing terms remain uncertain; any delay could depress the stock.
Background
Integer (NYSE:ITGR) is a leading contract development and manufacturing organization for medical devices. The acquisition by KKR‑managed funds was announced in August and has now been approved by shareholders.
Ticker impact
Integer shareholders approved the $5.7 bn KKR acquisition, confirming the deal and clearing a major corporate event.
likely upward pressure as investors price in the acquisition premium and future growth capital.
The approval is a primary disclosure of a large‑scale M&A transaction; market participants typically bid the target higher on completion certainty.
Market effects
Strengthens consolidation trend in medtech CDMO space, may prompt peers to explore similar deals.
Positive for US medtech sector; limited broader market effect.
Modest, confined to healthcare manufacturing niche.
Counterpoint
Deal could lead to integration challenges and potential cost overruns, weighing on long‑term value.
Key entities
- companyInteger
Medical device CDMO target of the acquisition.
- investment_firmKKR
Private‑equity sponsor acquiring Integer.
